Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 32, 2023 - Issue 11
Submit an article Journal homepage
532
Views
0
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Retatrutide showing promise in obesity (and type 2 diabetes)

Sheila A DoggrellSchool of Pharmacy and Medical Sciences, Gold Coast Campus, Griffith University, Queensland, AustraliaCorrespondence[email protected]
View further author information
Pages 997-1001 | Received 24 Sep 2023, Accepted 09 Nov 2023, Published online: 20 Nov 2023

References

  • Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi: 10.1056/NEJMoa2301972
  • Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, G-LP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-ling, placebo and active controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402:529–544. doi: 10.1016/S0140-6736(23)01053-X
  • World Health Organisation. Obesity and overweight. Available at https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [Last accessed 30 Aug, 2023]
  • Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851. doi: 10.1056/NEJMoa1901118
  • Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi: 10.1056/NEJMoa2032183
  • Kopp FK, Aroda VR, Do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:705–719. doi: 10.1016/S0140-6736(23)01185-6
  • Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–155. doi: 10.1016/S0140-6736(21)01324-6
  • Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi: 10.1056/NEJMoa2206038
  • Coskun C, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34:1234–1247. doi: 10.1016/j.cmet.2022.07.013
  • Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. doi: 10.1016/S0140-6736(22)02033-5
  • Seviiri M, Lynch BM, Hodge AM, et al. Resting heart rate, temporal changes in resting heart rate, and overall and cause-specific mortality. Heart. 2018;104:1075–1085. 16. doi: 10.1136/heartjnl-2017-312251
  • Böhm M, Schumacher H, Teo KK, et al. Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. Eur Heart J. 2020;41(2):231–238. doi: 10.1093/eurheartj/ehy808
  • Doggrell SA. Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity. Expert Opin Investig Drugs. 2023;23:355–359. doi: 10.1080/13543784.2023.2206560
  • Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827
  • Le Roux CW, Hankosky ER, Wang D, et al. Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: an indirect treatment comparison. Diabetes Obes Metab. 2023;25:2626–2633. doi: 10.1111/dom.15148
  • Boye K, Ross M, Mody R, et al. Patients’ preferences for once-daily oral versus once-weekly injectable diabetes medication: the REVISE study. Diabetes Obes Metab. 2021;23:508–519. doi: 10.1111/dom.14244
  • ClinicalTrials.Gov a study of retatrutide (LY3437943) in participants who have obesity or overweight (TRIUMP-1). [Last accessed, 18 Sep 2023] https://clinicaltrials.gov/study/NCT05929066?term=retatrutide&rank=2
  • ClinicalTrials.Gov a study of retatrutide (LY3437943) in participants with type 2 diabetes mellitus who have obesity or overweight (TRIUMP=2). [Last accessed, 18 Sep 23] https://www.clinicaltrials.gov/study/NCT05929079?term=ly3437943&page=2&rank=15
  • ClinicalTrials.Gov a study of retatrutide (LY3437943) in participants with obesity and cardiovascular disease (TRIUMPH-3). [Last accessed, 18 Sep 2023] https://clinicaltrials.gov/study/NCT05882045?term=retatrutide&rank=1

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.